share_log

東陽光長江藥業：有關可能轉讓本公司股份的內幕消息 不尋常的股價波動 根據收購守則規則3.7作出的公告及有關本公司可能合併的內幕消息及恢復買賣

HEC CJ PHARM: INSIDE INFORMATION IN RELATION TO A POSSIBLE TRANSFER OF SHARES IN THE COMPANY UNUSUAL PRICE MOVEMENTS ANNOUNCEMENT PURSUANT TO RULE 3.7 OF THE TAKEOVERS CODE AND INSIDE INFORMATION IN RELATION TO A POSSIBLE MERGER OF THE COMPANY AND RESUMPTI

香港交易所 ·  Mar 8 05:31
Summary by Moomoo AI
宜昌東陽光長江藥業股份有限公司（「東陽光長江」）於2024年3月8日宣布，其控股股東廣東東陽光藥業將轉讓持有的約25.71%股份給香港東陽光，轉讓對價為每股9.14港元，總對價約為20.67億港元。此次股份轉讓是集團重組的一部分，並可能涉及廣東東陽光藥業與東陽光長江之間的合併。廣東東陽光藥業的最終實益擁有人郭梅蘭女士及張寓帥先生共同實益擁有約62.12%的股權，並在交割前後持股比例不變。此外，廣東東陽光藥業正考慮以換股方式吸收合併東陽光長江，目的是打造一體化的醫藥產業鏈，提高運營效率，並共用研發平台。合併完成後，東陽光長江在聯交所的上市地位將被取消，而廣東東陽光藥業將提供新H股作為東陽光長江H股的註銷價，並計劃在聯交所主板上市。目前，合併及上市計劃仍處於初步階段。
宜昌東陽光長江藥業股份有限公司（「東陽光長江」）於2024年3月8日宣布，其控股股東廣東東陽光藥業將轉讓持有的約25.71%股份給香港東陽光，轉讓對價為每股9.14港元，總對價約為20.67億港元。此次股份轉讓是集團重組的一部分，並可能涉及廣東東陽光藥業與東陽光長江之間的合併。廣東東陽光藥業的最終實益擁有人郭梅蘭女士及張寓帥先生共同實益擁有約62.12%的股權，並在交割前後持股比例不變。此外，廣東東陽光藥業正考慮以換股方式吸收合併東陽光長江，目的是打造一體化的醫藥產業鏈，提高運營效率，並共用研發平台。合併完成後，東陽光長江在聯交所的上市地位將被取消，而廣東東陽光藥業將提供新H股作為東陽光長江H股的註銷價，並計劃在聯交所主板上市。目前，合併及上市計劃仍處於初步階段。
YICHANG DONGSUN CHANGJIANG PHARMACEUTICAL CO., LTD. (“EAST SUNSHINE CHANGJIANG”) ANNOUNCED ON 8 MARCH 2024 THAT ITS CONTROLLING SHAREHOLDER GUANGDONG SUNSHINE PHARMACEUTICALS WILL TRANSFER ITS HOLDING OF APPROXIMATELY 25.71% SHARES TO HONG KONG DONGSUN AT A PRICE OF HK$9.14 PER SHARE FOR A TOTAL PRICE OF APPROXIMATELY HK$20.67 BILLION. This share transfer is part of the Group's restructuring and may involve a merger between Guangdong Sunlight Pharmaceutical and Dongguang Yangtze. The ultimate beneficial owners of Guangdong Sunlight Pharmaceutical, Ms. Kwok Meilan and Mr. Zhang Jianshuai jointly hold approximately 62.12% of the shareholding, and the shareholding ratio is unchanged before and after the offering. IN ADDITION, GUANGDONG SUNSHINE PHARMACEUTICAL IS CONSIDERING ACQUIRING THE MERGED DONGSUN CHANGJIANG BY EXCHANGE OF SHARES, AIMING TO CREATE AN INTEGRATED...Show More
YICHANG DONGSUN CHANGJIANG PHARMACEUTICAL CO., LTD. (“EAST SUNSHINE CHANGJIANG”) ANNOUNCED ON 8 MARCH 2024 THAT ITS CONTROLLING SHAREHOLDER GUANGDONG SUNSHINE PHARMACEUTICALS WILL TRANSFER ITS HOLDING OF APPROXIMATELY 25.71% SHARES TO HONG KONG DONGSUN AT A PRICE OF HK$9.14 PER SHARE FOR A TOTAL PRICE OF APPROXIMATELY HK$20.67 BILLION. This share transfer is part of the Group's restructuring and may involve a merger between Guangdong Sunlight Pharmaceutical and Dongguang Yangtze. The ultimate beneficial owners of Guangdong Sunlight Pharmaceutical, Ms. Kwok Meilan and Mr. Zhang Jianshuai jointly hold approximately 62.12% of the shareholding, and the shareholding ratio is unchanged before and after the offering. IN ADDITION, GUANGDONG SUNSHINE PHARMACEUTICAL IS CONSIDERING ACQUIRING THE MERGED DONGSUN CHANGJIANG BY EXCHANGE OF SHARES, AIMING TO CREATE AN INTEGRATED PHARMACEUTICAL INDUSTRY CHAIN, IMPROVE OPERATIONAL EFFICIENCY, AND SHARE R&D PLATFORMS. After the completion of the merger, Dongguang Changjiang's listed position on the exchange will be canceled, and Guangdong Sunlight Pharmaceutical will offer the new H shares as the write-off price of Dongsun Changjiang H shares and plans to list on the exchange's main board. At present, the merger and listing plans are still in the preliminary stages.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more